Vestipitant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vestipitant
Vestipitant structure.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C23H21F10N3O
Molar mass 545.416 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Vestipitant (INN)[1]:98 is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug,[2][3] and as a treatment for tinnitus[4] and insomnia.[5]

See also[edit]

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). World Health Organization. Retrieved 17 November 2016. 
  2. ^ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy. 3 (3): 140–2. PMID 18632487. doi:10.3816/SCT.2006.n.011. 
  3. ^ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR; et al. (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 18 (10): 729–50. PMID 18657401. doi:10.1016/j.euroneuro.2008.06.002. 
  4. ^ Clinical trial number NCT00394056 for "Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss" at ClinicalTrials.gov
  5. ^ Ratti, E; et al. (December 2013). "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.". Sleep (2013). 36 (12): 1823–30. PMC 3825431Freely accessible. PMID 24293756. doi:10.5665/sleep.3208.